{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:02:20Z","timestamp":1760299340686},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T00:00:00Z","timestamp":1460592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T00:00:00Z","timestamp":1460592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An anticancer bioactive peptide (ACBP), goat peroxiredoxin-5 (gPRDX5), was identified from goat-spleen extract after immunizing the goat with gastric cancer-cell lysate. Its amino acid sequence was determined by employing 2D nano-LC-ESI-LTQ-Orbitrap MS\/MS combined with Mascot database search in the goat subset of the Uniprot database. The recombinant gPRDX5 protein was acquired by heterogeneous expression in <jats:italic>Escherichia coli.<\/jats:italic> Subsequently, the anti-cancer bioactivity of the peptide was measured by several kinds of tumor cells. The results indicated that the gPRDX5 was a good anti-cancer candidate, especially for killing B16 cells. However, the peptide was found to be unstable without modification with pharmaceutical excipients, which would be a hurdle for future medicinal application. In order to overcome this problem and find an effective way to evaluate the gPRDX5, nanoparticle formation, which has been widely used in drug delivery because of its steadiness in application, less side-effects and enhancement of drug accumulation in target issues, was used here to address the issues. In this work, the gPRDX5 was dispersed into nanoparticles before delivered to B16 cells. By the nanotechnological method, the gPRDX5 was stabilized by a fast and accurate procedure, which suggests a promising way for screening the peptide for further possible medicinal applications.<\/jats:p>","DOI":"10.1038\/srep24467","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T12:16:56Z","timestamp":1460636216000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The identification of goat peroxiredoxin-5 and the evaluation and enhancement of its stability by nanoparticle formation"],"prefix":"10.1038","volume":"6","author":[{"given":"Xiaozhou","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"key":"BFsrep24467_CR1","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre, L. A. et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 65, 87\u2013108 (2015).","journal-title":"CA: a cancer journal for clinicians"},{"key":"BFsrep24467_CR2","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.1021\/nn405632s","volume":"7","author":"Y Yan","year":"2013","unstructured":"Yan, Y. et al. Particle carriers for combating multidrug-resistant cancer. ACS nano. 7, 9512\u20139517 (2013).","journal-title":"ACS nano."},{"key":"BFsrep24467_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.5306\/wjco.v5.i2.86","volume":"5","author":"L Minig","year":"2014","unstructured":"Minig, L. et al. Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB. World journal of clinical oncology. 5, 86\u201392 (2014).","journal-title":"World journal of clinical oncology"},{"key":"BFsrep24467_CR4","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","volume":"60","author":"T J.D. Byrne","year":"2008","unstructured":"J.D. Byrne, T. et al. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60, 1615\u20131626 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFsrep24467_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang, C. et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558 and in vivo toxicology in non-human primates. Cancer immunology research. 2, 846\u2013856 (2014).","journal-title":"Cancer immunology research"},{"key":"BFsrep24467_CR6","doi-asserted-by":"crossref","unstructured":"Wiesner, J. et al. Therapeutic Potential of Anti-Microbial Peptides from Insects. (ed. Vilcinskas, A. ) 99\u2013100 (Springer: Netherlands,, 2011).","DOI":"10.1007\/978-90-481-9641-8_3"},{"key":"BFsrep24467_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0163-7827(03)00032-8","volume":"42","author":"T P. Sapra","year":"2003","unstructured":"P. Sapra, T. et al. Ligand-targeted liposomal anticancer drugs. Lipid Res. 42, 439\u2013462 (2003).","journal-title":"Lipid Res"},{"key":"BFsrep24467_CR8","first-page":"607","volume":"41","author":"YY Zhao","year":"2006","unstructured":"Zhao, Y. Y. et al. Effects of anti-cancer bioactive peptide on cell cycle in human nasopharyngeal carcinoma strain CNE. Zhonghua er bi yan hou tou jing wai ke za zhi\u2009=\u2009Chinese journal of otorhinolaryngology head and neck surgery. 41, 607\u2013611 (2006).","journal-title":"Zhonghua er bi yan hou tou jing wai ke za zhi\u2009=\u2009Chinese journal of otorhinolaryngology head and neck surgery"},{"key":"BFsrep24467_CR9","first-page":"382","volume":"9","author":"MR Yan","year":"2002","unstructured":"Yan, M. R. et al. Effect of anti-gastric cancer biological peptide on lactic dehydrogenase isoenzyme. China J Cancer Prev Treat. 9, 382\u2013383 (2002).","journal-title":"China J Cancer Prev Treat"},{"key":"BFsrep24467_CR10","first-page":"26","volume":"2","author":"XL Su","year":"1999","unstructured":"Su, X. L. et al. The experimental research on anti-gastric cancer active peptide. Int J Moden Cancer Ther. 2, 26\u201327 (1999).","journal-title":"Int J Moden Cancer Ther."},{"key":"BFsrep24467_CR11","first-page":"3","volume":"23","author":"SU LIYA","year":"2010","unstructured":"LIYA, S. U. et al. Anticancer bioactive peptide suppresses human gastric cancer growth through modulation of apoptosis and the cell cycle. Oncol Rep. 23, 3\u20139 (2010).","journal-title":"Oncol Rep."},{"key":"BFsrep24467_CR12","first-page":"3","volume":"26","author":"JF Hou","year":"2004","unstructured":"Hou, J. F. et al. Effect of anticancer bioactive peptide on leukemia mice. Acta Academiae Med Neimongol. 26, 3\u20136 (2004).","journal-title":"Acta Academiae Med Neimongol"},{"key":"BFsrep24467_CR13","first-page":"301","volume":"12","author":"XH Quan","year":"2005","unstructured":"Quan, X. H. et al. Effect of anti-gastric cancer biological peptide on mice and induction of TNF. Chin J Cancer Biother. 12, 301\u2013302 (2005).","journal-title":"Chin J Cancer Biother."},{"key":"BFsrep24467_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jprot.2012.11.013","volume":"78","author":"CC Clement","year":"2013","unstructured":"Clement, C. C. et al. Protein expression profiles of human lymph and plasma mapped by 2D-DIGE and 1D SDS\u2013PAGE coupled with nanoLC\u2013ESI\u2013MS\/MS bottom-up proteomics. Journal of proteomics. 78, 172\u2013187 (2013).","journal-title":"Journal of proteomics"},{"key":"BFsrep24467_CR15","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1212\/NXI.0000000000000155","volume":"2","author":"V Singh","year":"2015","unstructured":"Singh, V. et al. Gray matter-related proteins are associated with childhood-onset multiple sclerosis. Neurology(R) neuroimmunology & neuroinflammation. 2, e155 (2015).","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"key":"BFsrep24467_CR16","first-page":"S82291","volume":"10","author":"H Yang","year":"2015","unstructured":"Yang, H. et al. A novel strategy for the discrimination of gelatinous Chinese medicines based on enzymatic digestion followed by nano-flow liquid chromatography in tandem with orbitrap mass spectrum detection. International journal of nanomedicine. 10, 4947\u20134955, S82291 (2015).","journal-title":"International journal of nanomedicine."},{"key":"BFsrep24467_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/btpr.2192","volume":"32","author":"S Masoomi Dezfooli","year":"2016","unstructured":"Masoomi Dezfooli, S., Tan, W. S., Tey, B. T., Ooi, C. W. & Hussain, S. A. Expression and purification of the matrix protein of Nipah virus in baculovirus insect cell system. Biotechnol Prog 32, 171\u2013177 (2016).","journal-title":"Biotechnol Prog"},{"key":"BFsrep24467_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2015012271","volume":"32","author":"VRS Silki","year":"2015","unstructured":"Silki, V. R. S. Emerging Potential of Nanosuspension-Enabled Drug Delivery: An Overview. Critical reviews in therapeutic drug carrier systems. 32, 535\u2013557 (2015).","journal-title":"Critical reviews in therapeutic drug carrier systems."},{"key":"BFsrep24467_CR19","doi-asserted-by":"publisher","first-page":"9806","DOI":"10.1039\/C5NR02470F","volume":"7","author":"H Ding","year":"2015","unstructured":"Ding, H. et al. Erythrocyte membrane-coated NIR-triggered biomimetic nanovectors with programmed delivery for photodynamic therapy of cancer. Nanoscale 7, 9806\u20139815 (2015).","journal-title":"Nanoscale"},{"key":"BFsrep24467_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","volume":"83","author":"L Zhang.","year":"2007","unstructured":"L., Zhang. et al. Nanoparticles inmedicine: therapeutic applications and developments Clin. Pharmacol. Ther. 83, 761\u2013769 (2007).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFsrep24467_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.drudis.2012.03.010","volume":"17","author":"H N. Ahmed","year":"2012","unstructured":"N. Ahmed, H. et al. Theranostic applications of nanoparticles in cancer. Drug Discov. Today. 17, 928\u2013934 (2012).","journal-title":"Drug Discov. Today."},{"key":"BFsrep24467_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/B978-0-12-391860-4.00006-9","volume":"508","author":"CW T. Stylianopoulos","year":"2012","unstructured":"T. Stylianopoulos, C. W. et al. Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol. 508, 109\u2013130 (2012).","journal-title":"Methods Enzymol."},{"key":"BFsrep24467_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejpb.2012.07.014","volume":"82","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide\/protein drugs and poorly water-soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics. 82, 219\u2013229 (2012).","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics."},{"key":"BFsrep24467_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.molmed.2015.01.001","volume":"21","author":"X Xu.","year":"2015","unstructured":"X., Xu. et al. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol. Med 21, 223\u2013232 (2015).","journal-title":"Trends Mol. Med"},{"key":"BFsrep24467_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3892\/mco.2013.91","volume":"1","author":"A Elamin","year":"2013","unstructured":"Elamin, A. et al. Peroxiredoxin V: A candidate breast tumor marker of population specificity. Molecular and clinical oncology. 1, 541\u2013549 (2013).","journal-title":"Molecular and clinical oncology"},{"key":"BFsrep24467_CR26","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.yexcr.2006.05.006","volume":"312","author":"A Kropotov","year":"2006","unstructured":"Kropotov, A. et al. Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. Experimental cell research. 312, 2806\u20132815 (2006).","journal-title":"Experimental cell research."},{"key":"BFsrep24467_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/03602550600685275","volume":"24","author":"M Ameri","year":"2006","unstructured":"Ameri, M. et al. Spray drying of biopharmaceuticals: stability and process considerations. DRY TECHNOL. 24, 763\u2013768 (2006).","journal-title":"DRY TECHNOL."},{"key":"BFsrep24467_CR28","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.ddtec.2008.11.001","volume":"5","author":"MJ Maltesen","year":"2008","unstructured":"Maltesen, M. J. et al. Drying methods for protein pharmaceuticals. Drug discovery today. Technologies. 5, e81\u201388 (2008).","journal-title":"Drug discovery today. Technologies"},{"key":"BFsrep24467_CR29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.addr.2011.02.001","volume":"63","author":"L Wu","year":"2011","unstructured":"Wu, L., Zhang, J. et al. Physical and chemical stability of drug nanoparticles. Advanced drug delivery reviews. 63, 456\u2013469 (2011).","journal-title":"Advanced drug delivery reviews."},{"key":"BFsrep24467_CR30","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1021\/bm500588x","volume":"15","author":"M Duran-Lobato","year":"2014","unstructured":"Duran-Lobato, M. et al. Surface-modified P(HEMA-co-MAA) nanogel carriers for oral vaccine delivery: design, characterization and in vitro targeting evaluation. Biomacromolecules. 15, 2725\u20132734 (2014).","journal-title":"Biomacromolecules."},{"key":"BFsrep24467_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ejps.2013.05.004","volume":"49","author":"RR Haj-Ahmad","year":"2013","unstructured":"Haj-Ahmad, R. R. et al. Compare and contrast the effects of surfactants (Pluronic\u00aeF-127 and Cremophor\u00aeEL) and sugars (\u03b2-cyclodextrin and inulin) on properties of spray dried and crystallised lysozyme. European Journal of Pharmaceutical Sciences. 49, 519\u2013534 (2013).","journal-title":"European Journal of Pharmaceutical Sciences."},{"key":"BFsrep24467_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4","volume":"63","author":"P Calvo.","year":"1997","unstructured":"P., Calvo. et al. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. Journal of Applied Polymer Science. 63, 125\u2013132 (1997).","journal-title":"Journal of Applied Polymer Science."},{"key":"BFsrep24467_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.tiv.2015.11.006","volume":"31","author":"M Forte","year":"2016","unstructured":"Forte, M. et al. Polystyrene nanoparticles internalization in human gastric adenocarcinoma cells. Toxicology in Vitro. 31, 126\u2013136 (2016).","journal-title":"Toxicology in Vitro."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep24467","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep24467.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep24467.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T18:20:03Z","timestamp":1672856403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep24467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,26]]}},"alternative-id":["BFsrep24467"],"URL":"https:\/\/doi.org\/10.1038\/srep24467","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,14]]},"assertion":[{"value":"27 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24467"}}